← Back to Clinical Trials
Recruiting NCT06791837

NCT06791837 Brain Blood Flow and Lactate in Non-obese and Obese Subjects

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06791837
Status Recruiting
Phase
Sponsor University of Missouri-Columbia
Condition Diabetes
Study Type OBSERVATIONAL
Enrollment 24 participants
Start Date 2025-05-01
Primary Completion 2027-03-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 45 Years
Study Type OBSERVATIONAL
All Conditions
Interventions
EXERCISE

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 24 participants in total. It began in 2025-05-01 with a primary completion date of 2027-03-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Cerebral blood flow (CBF) is essential for maintaining brain health and function, as it ensures delivery oxygen and nutrients necessary to support neuronal activity. Reduced CBF can impair the brain's ability to meet its metabolic demands, leading to deficits in cognitive ability. Impairments in CBF are associated with cognitive decline and neurodegenerative disease such as Alzheimer's and dementia. Many factors influence CBF, but recently lactate has emerged as a key player. Blood glucose has long been considered the primary fuel for the brain, but emerging evidence indicates that lactate may be the preferred fuel for neurons, and lactate may become even more important under stressful conditions. Individuals with obesity often have impaired lactate metabolism resulting in higher resting blood lactate concentrations and reduced ability to clear lactate after a physiological stress. At the same time, it is known that exercise is a powerful intervention for improving lactate metabolism. Thus, this project seeks to investigate the role of lactate in brain blood flow in individuals with and without obesity as well as establish if short term exercise training (individuals with obesity only) will alter circulating lactate concentrations at rest and in response to exercise.

Eligibility Criteria

Inclusion Criteria: healthy adult men and women 18-45 years of age BMI 18-40 kg/m2 not pregnant, premenopausal with regular menstrual cycles not breastfeeding non-nicotine users Exclusion Criteria: medications known to affect sleep, autonomic control, blood lactate levels or metabolic, or cardiovascular function (PI discretion) self-reported history of hepatic, renal, pulmonary, cardiovascular, or neurological disease, stroke or neurovascular disease, bleeding/clotting disorders, sleep apnea or other sleep disorders, diabetes, history of alcoholism or substance abuse major cardiovascular event or surgical procedure within the past three months hypertension (\>140/90 mmHg or at PIs discretion). \-

Contact & Investigator

Central Contact

Matt McDonald, MS

✉ mjmdr4@missouri.edu

📞 6185815501

Principal Investigator

Jill Kanaley, PhD

PRINCIPAL INVESTIGATOR

University of Missouri-Columbia

Frequently Asked Questions

Who can join the NCT06791837 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 45 Years, studying Diabetes. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06791837 currently recruiting?

Yes, NCT06791837 is actively recruiting participants. Contact the research team at mjmdr4@missouri.edu for enrollment information.

Where is the NCT06791837 trial being conducted?

This trial is being conducted at Columbia, United States.

Who is sponsoring the NCT06791837 clinical trial?

NCT06791837 is sponsored by University of Missouri-Columbia. The principal investigator is Jill Kanaley, PhD at University of Missouri-Columbia. The trial plans to enroll 24 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology